Zobrazeno 1 - 10
of 14
pro vyhledávání: '"E A Pyadushkina"'
Autor:
E A Pyadushkina, K V Gerasimova, S V Goryainov, Vitaly Vladimirovich Omelyanovsky, M V Avksentyeva, I S Krysanov
Publikováno v:
Современная ревматология, Vol 6, Iss 4, Pp 89-96 (2012)
Objective: to make a pharmacoeconomic analysis of the use of oral (a 150-mg tablet once a month) and injectable (a solution for intravenous bolus injection of 3 mg in 3 ml once every 3 months) ibandronate in patients with postmenopausal osteoporosis
Externí odkaz:
https://doaj.org/article/133612481081496fa034b2b7e95c2653
Publikováno v:
Современная ревматология, Vol 15, Iss 1, Pp 119-127 (2021)
Objective: to evaluate the economic impact of the use of various biologic disease-modifying antirheumatic drugs (bDMARDs) from the group of inhibitors of interleukins (iIL) 12/23 and iIL17 in adult patients with psoriatic arthritis (PsA) with insuffi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0314b6661c958691e600825bc48a1077
https://mrj.ima-press.net/mrj/article/view/1110
https://mrj.ima-press.net/mrj/article/view/1110
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 1, Pp 4-13 (2018)
Actuallity. Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease caused by the production of antibodies to the platelet and megakaryocytes membrane structure, which causes to increase the platelet destruction, but also inadequate thromb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::17d89035c705832ec0315220f5f077f6
https://www.clinvest.ru/jour/article/view/212
https://www.clinvest.ru/jour/article/view/212
Publikováno v:
Вестник травматологии и ортопедии имени Н.Н. Приорова, Vol 0, Iss 4, Pp 28-33 (2016)
Clinical economic analysis of the use of enoxaparin, rivaroxaban and dabigatran etexilate for venous thromboembolism prophylaxis (VTP) in patients after vast orthopaedic operations within the RF public health system was performed. For cost calculatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::237f034ff2f6fe85dc37b782160454cb
https://www.cito-vestnik.ru/jour/article/view/135
https://www.cito-vestnik.ru/jour/article/view/135
Publikováno v:
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimentalclinical gastroenterology. (3)
We conducted clinical and economic analysis of the protease inhibitor simeprevir versus currently available in Russia protease inhibitors (boceprevir and telaprevir) in combination with pegylated interferon and ribavirin and dual therapy with pegylat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cf77547309c6ff7ce6970f545da435cc
https://pubmed.ncbi.nlm.nih.gov/26281179
https://pubmed.ncbi.nlm.nih.gov/26281179
Publikováno v:
Фармакоэкономика, Vol 16, Iss 2, Pp 236-247 (2023)
Background. The therapy of chronic pain in cancer patients is a highly topical issue for the modern health care system. Intense pain syndrome involves the prescription of strong opioid analgesics (ОА), most of which are classified as narcotic drugs
Externí odkaz:
https://doaj.org/article/10926aa9fe3143f387f0f137a937dee8
Autor:
E. V. Derkach, E. A. Pyadushkina, M. V. Avxentyeva, T. V. Boyarskaya, E. E. Yagnenkova, A. S. Mokrova, M. M. Maryanyan
Publikováno v:
Фармакоэкономика, Vol 13, Iss 3, Pp 225-239 (2020)
Diagnosis-Related Groups (DRG) for the payment for biological therapy were created at the stage of the pilot project and their coefficients of input intensity were not revised since then. The expansion of the range of genetically-engineered biologica
Externí odkaz:
https://doaj.org/article/02c332ca041f48a4bdd89718ab193121
Autor:
E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov
Publikováno v:
Фармакоэкономика, Vol 14, Iss 2 (2021)
Background. The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma (RRMM), but the question of whether these expensive options can be financially secured rema
Externí odkaz:
https://doaj.org/article/5e3ab6bf218b4d07a9b2e4a646e4f6a2
Autor:
E. A. Pyadushkina
Publikováno v:
Фармакоэкономика, Vol 10, Iss 1, Pp 19-28 (2017)
Aims of the study: to assess health care costs of the use of biological agents (vedolizumab and various TNF-α inhibitors) in adult patients with moderate to severe active ulcerative colitis (UC) and moderate or severe active Crohn’s disease (CT) w
Externí odkaz:
https://doaj.org/article/30d464ce14864b2296eace8196969868
Autor:
E. A. Pyadushkina, M. Yu. Frolov
Publikováno v:
Фармакоэкономика, Vol 9, Iss 3, Pp 38-47 (2016)
Aims of study: 1) development of a model for forecasting of impact of Lacosamide administration for antiseizure therapy of local convulsions in patients, who are resistant to previous antiseizure therapy, for the account of healthcare and social secu
Externí odkaz:
https://doaj.org/article/a4bcc9eca174474cac143a3f38290042